dc.contributor.author | Sauereisen, Sandra | eng |
dc.contributor.author | Castelli, Gregory | eng |
dc.contributor.other | Family Physicians Inquiries Network | eng |
dc.date.issued | 2020 | eng |
dc.description | Review of: Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440-453. | eng |
dc.description.abstract | A better approach to preventing active TB? Nine months of isoniazid prevents active TB in those with latent disease. But is there a shorter, less toxic option? PRACTICE CHANGER: Use 4 months of rifampin instead of 9 months of isoniazid to treat adults with latent tuberculosis; rifampin is associated with fewer adverse events and higher completion rates. STRENGTH RECOMMENDATION: B: Based on a randomized controlled trial and a previous Cochrane review. | eng |
dc.description.statementofresponsibility | Sandra Sauereisen, MD, MPH; Gregory Castelli, PharmD, BCPS, BC-ADM UPMC; St. Margaret Family Medicine Residency, Pittsburgh, PA | eng |
dc.identifier.uri | https://hdl.handle.net/10355/74641 | |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Priority Updates to Research Literature (PURLs) (2020) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 69, no. 01 (January 2020): 37-38. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject.other | Tuberculosis | eng |
dc.subject.other | Isoniazid | eng |
dc.subject.other | Rifampin | eng |
dc.subject.other | Adults | eng |
dc.title | A better approach to preventing active TB? | eng |
dc.type | Article | eng |